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Background. Although our comprehension of nonrheumatic aortic stenosis (NRAS) has increased substantially during the last
decade, less is known about the histopathology of rheumatic aortic stenosis (RAS). The aim of this study was to investigate
rheumatic aortic stenosis by means of analyses previously used in nonrheumatic stenosis.Material and Methods. Valve specimens
were obtained from 39 patients referred to hospital due to significant aortic stenosis. According to established macroscopic
criteria the valves were divided into two groups consisting of 29 NRAS and 10 RAS valves. Mononuclear inflammatory cells
and apolipoproteins were investigated using immunohistochemical analyses. Results. The localisation of calcification differed
in tricuspid nonrheumatic valves when compared to bicuspid nonrheumatic and rheumatic valves. The RAS valves revealed a
lower degree of T lymphocyte infiltration compared with the NRAS valves. Infiltration of macrophages was seen in all valves
and there were no differences regarding deposition of apolipoprotein. Conclusion. Rheumatic and nonrheumatic aortic stenotic
valves show a similar and significant chronic inflammation. The similarities regarding the localisation of calcification indicate that
the valve anomaly/morphology can influence the pathogenesis of aortic stenosis. Finally, our findings highlight the question of a
postinflammatory valvular disease of other causes than rheumatic fever.
1. Introduction
At the beginning of the 20th century, the incidence of
rheumatic fever in theUnited States exceeded 100 per 100,000
population [1], and rheumatic heart disease was consequently
the leading cause of heart valve illness. During the same
century a gradual decrease in the incidence of rheumatic
fewer was seen. The incidence ranged between 40 and 65 per
100,000 between 1935 and 1960 and is currently estimated at
less than 2 per 100,000.
Improved socioeconomic conditions in thewesternworld
during the late half of the 20th century, with an increased life
span, dramatically changed the aetiologic panorama of aortic
stenosis. The so-called degenerative, nonrheumatic aortic
stenosis (NRAS) has become the foremost cause of significant
aortic valve obstruction. In adults undergoing aortic valve
replacement for symptomatic aortic stenosis in the USA,
nonrheumatic tricuspid aortic stenosis (NRAS-T) accounts
for 51% of cases, bicuspid aortic stenosis (NRAS-B) for 36%,
and rheumatic aortic stenosis (RAS) for 9% [2].
However, the presence of an aortic stenosis of rheumatic
origin has been under debate. The sole pathognomonic
feature of rheumatic valve disease, the Aschoff ’s granuloma,
is virtually never found in heart valve tissue and thus, reliable
diagnostic criteria is lacking. Presumed rheumatic stenotic
aortic valves have been investigated in numerous studies with
different approaches, all trying to master the nonattendant
pathognomonic sign of rheumatic heart valve disease [3–6].
During the last two decades the knowledge of NRAS
has increased considerably [7–12]. The aim of the present
study was to compare RAS with NRAS, utilizing some of the
analyses that we have previously performed on nonrheumatic
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heart valves [13, 14], and to investigate whether these analyses
could contribute to our understanding of the stenotic disease
of the aortic valve.
2. Material and Methods
Thirty-nine patients, consecutively accepted for surgery due
to severe aortic valve stenosis, were enrolled in the study.
Diagnosis was made by preoperative Doppler echocardio-
graphy. According to established macroscopic criteria for
rheumatic heart valve disease [15, 16] the 39 stenotic aortic
valves were divided into rheumatic aortic valves and non-
rheumatic aortic valves.
2.1.Histopathological Analyses. After fixation in 10% formalin
the valves were measured and examined macroscopically as
described by Schoen [16]. A representative sample regard-
ing calcification and fibrous thickening was taken from
each valve. One section was taken from each cusp, each
representing areas of thickening and calcification, but also
including areas with minimal or no macroscopical changes,
as calcification and fibrosis are not uniform processes. All
grossly calcified valves were decalcified in 10% formic acid
solution for 24 hours, then processed and cut in 4𝜇msections
and stained with hematoxylin-eosin (H&E), van Gieson
(VG), von Kossa, and Perls stains. Reference samples of all
stains before and after decalcificationwere compared, thereby
ensuring that the process of decalcification did not interfere
with the staining and hence the result/interpretation of the
staining.
Calcification was estimated by analysis of the gross spec-
imen and by microscopic analysis of sections stained with
the von Kossa stain. The extent of valvular calcification was
arbitrarily graded as previously described by Subramanian
et al. [17] as: 0 = absent, 1+ = mild, 2+ = moderate, or 3+ =
severe. The degree of cusp thickening was arbitrarily graded
as: 0 = absent, 1+ = increased valvular thickness only in the
apposition area of the valve, 2+ = increased valvular thickness
beyond the apposition area but not involving the entire
valve, or 3+ = increased thickness of the valve by fibrosis
in the entire valve or more limited areas of fibrosis which
distorts the cusp shape.The degree of microcalcifications was
semiquantitatively and arbitrarily categorized as: 0 = absent,
trace = deposits not clearly visible on low power (25x), mild =
scattered loose deposits or dense focal deposits covering <2
high-power fields (HPFs) (400x), moderate = dense deposits
in >2 HPFs, and <6 HPFs, or severe = dense deposits in 6 or
more HPFs. Furthermore, both the localisation of the calci-
fication and the localisation of the fibrosis were investigated.
Thevalveswere evaluated for fresh haemorrhage on theH&E-
stained sections and for old haemorrhage (haemosiderin
deposits) with the Perls stain. Similar semiquantitative, arbi-
trary categorisation was used for both, which were graded
as: 0 = absent, (+) = trace = haemosiderin deposits or
fresh haemorrhage seen focally in 1 HPF (400x), mild =
haemosiderin deposits or fresh haemorrhage seen in 2
HPFs, moderate = deposits seen in >2 HPFs, and <6 HPFs,
severe = deposits in 6 or more HPFs. One reviewer, blinded
both to the type of valve dysfunction and to the clinical
history, performed all histological and immunohistochemical
analyses.
2.2. Immunohistochemical Studies. For the determination
of different mononuclear inflammatory cells, additional
sections were stained with antibodies for CD3 (pan-T
lymphocyte antigen, Dako, Carpinteria, CA, USA; 1:400),
CD20 (pan-B lymphocyte antigen, Dako; 1:400), and CD68
(macrophage antigen, DakoCytomation, Glostrup, Denmark,
1:100). The valves were investigated regarding the presence
and localisation of mononuclear cell infiltration. The degree
of mononuclear cell infiltration was semiquantitatively and
arbitrarily determined as previously described by Stratford
et al. [18]: 0 = no inflammatory cells present, 1+ = occasional
scattered cells or one group of 20 cells in a cusp section, 2+ =
several groups of 20 cells or more in a cusp section, or 3+ =
many groups of >20 cells or one group of 100 cells or more in
a cusp section.
For determination of the presence of apolipoprotein (apo)
A-I and apo B, sections were stained with goat polyclonal
antibody to human apo A-I (Abcam Ltd., UK; 1:800) and
goat polyclonal antibody to human apo B (Abcam Ltd.; 1:800)
and visualized with LSAB DakoCytomation K0690. Staining
was by TechMate 500 according to standard protocol. The
degree of apolipoprotein deposition was semiquantitatively
categorized as follows: 0 = absent, 1+ = deposits in <5% of
the cusp, 2+ = deposits in 5–25% of the cusp, 3+ = deposits
in 26–50% of the cusp, 4+ = deposits in 51–75% of the
cusp, 5+ = deposits in >75% of the cusp. If more than one
cusp was involved, the one with the greatest deposits was
scored.
2.3. Statistical Analyses. Comparisons between groups were
performed using the 𝑡-test for parametric values and the
Mann-Whitney test for nonparametric, nondependent sam-
ples. The data were considered significant at 𝑃 < 0.05 level.
3. Results
Ten out of 39 valves (7 men, 3 women, mean age 64±7 years)
revealed postinflammatory changes with severely distorted
and fused cusp margins (commissural fusion), resulting in
a central triangular orifice. These valves were considered
as RAS while the remaining 29 stenotic aortic valves were
judged as NRAS. In 1/10 RAS, the valve was bicuspid, whereas
the remaining 9/10 valves were tricuspid. Among NRAS
valves, 12 valves (7 men and 5 women, mean age 67 ± 8
years) were considered to be bicuspid (NRAS-B) and 17 valves
(7 men, 10 women, mean age 71 ± 7 years) to be tricuspid
(NRAS-T). Clinical characteristics of RAS and NRAS groups
are presented in Table 1.
Three out of 10 (30%) RAS patients and 2/29 (7%) NRAS
patients had a history of rheumatic fever. Two RAS patients
with a history of rheumatic fever also revealed a significant
mitral valve stenosis, while the third RAS patient had been
operated on 12 years earlier because of mitral valve stenosis.
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Table 1: Clinical characteristics in RAS and NRAS groups.
Characteristic RAS (𝑛 = 10) NRAS (𝑛 = 29)
Mean age ± SD (years) 64 ± 7 n.s. 69 ± 7
Male gender, 𝑛 (%) 7 (70) n.s. 14 (48)
Current/ex-smokers 1/7 <0,05 3/6
Hypertension, 𝑛 (%) 1 (10) n.s. 5 (17)
Diabetes, 𝑛 (%) 0 n.s. 3 (10)
Angina pectoris, 𝑛 (%) 5 (50) n.s. 19 (66)
Prior myocardial infarction, 𝑛 (%) 1 (10) n.s. 2 (7)
Prior cerebrovascular event, 𝑛 (%) 1 (10) n.s. 2 (7)
Peripheral arterial disease, 𝑛 (%) 1 (10) n.s. 1 (3)
Coronary angiography, 𝑛 (%) 9 (90) n.s. 29 (100)
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Figure 1: (a) Destruction of architecture in RAS as compared to NRAS; data given as percent (%) of (𝑛). (b) Degree of neovascularisation in
RAS as compared to NRAS, <1/3 = in the basal third of valve cusp, >1/3 = beyond basal third of valve cusp; data given as percent (%) of (𝑛).
RAS = rheumatic aortic stenosis, NRAS = nonrheumatic aortic stenosis.
The remaining 7 RAS patients presented normal mitral valve
leaflets with mostly mild mitral regurgitation.
3.1. Histopathological and Immunohistochemical Analyses.
Complete fibrous destruction of the normal layered architec-
ture was seen in 3/10 (30%) RAS valves and in 5/29 (17%)
NRAS valves (Figure 1(a)). However, several valves revealed
partial destruction and only one valve, a nonrheumatic
tricuspid valve, had completely normal architecture.
All the aortic valves, rheumatic as well as nonrheumatic,
revealed mild to moderate cusp thickening. The fibrosis
was in most cases localised diffusely. Only two valves,
one rheumatic valve and one nonrheumatic, bicuspid valve,
showed fibrosis at the apposition area. Three out of 10 (30%)
RAS valves and 12/29 (41%) NRAS valves showed neovas-
cularisation characterised by small irregular, thick walled
and thin walled vessels within the basal third of the cusp
(Figure 1(b)). Among valves revealing neovascularisation,
neovessels were seen beyond the basal third of the valve in
1/3 RAS valves and 4/12 NRAS valves.
Calcification was seen in all valves, ranging from mild
to severe and without significant differences between the
groups. Whereas the NRAS-T valves revealed calcification
predominantly at the base of the cusp, the calcification in
the majority of the RAS and NRAS-B valves was localised
diffusely (Figure 2).
Due to our method of decalcification in 10% formic acid
solution for 24 hours, we were unable to evaluate the von
Kossa stain for mineralization, except in a few valves.
T lymphocytes were seen in 8/10 (80%) of the RAS and
26/29 (90%) of the NRAS valves.The degree of T lymphocyte
infiltration was significantly lower in RAS than in NRAS
valves (Figure 3(a)) while macrophages were abundantly
present in both types of valves without any significant
difference (Figure 3(b)).
B lymphocytes were detected in 5/10 (50%) RAS valves,
6/12 (50%) NRAS-B valves, and 8/17 (47%) NRAS-T valves.
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IRAS-T versus IRAS-B𝑃 < 0.05
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Figure 2: Localisation of calcification; number of valves given as
percent (%) of (𝑛). RAS = rheumatic aortic stenosis, NRAS = non
rheumatic aortic stenosis.
Plasma cells were revealed in 5/10 (50%) RAS, 5/12 (42%)
NRAS-B, and 3/17 (18%) NRAS-T valves.
Apolipoproteins were detected in all valves without any
significant differences regarding the degree of either apo B or
apo A-I (Figure 4).
4. Discussion
In the present study 10 stenotic aortic valves, defined as RAS
on the basis of macroscopic postinflammatory fusion of the
commissures, were investigated by means of histopathologi-
cal and immunohistochemical techniques previously used for
NRAS valves. According to our data the RAS valves revealed
signs of chronic inflammation, including inflammatory cell
infiltration, calcification, and deposition of apolipoproteins,
in much the same manner as has previously been shown in
NRAS valves. Minor differences were seen however.
Rheumatic heart valve disease is a well known, late,
inflammatory and nonsuppurative complication of group A,
streptococcal pharyngitis. In the western world rheumatic
heart valve disease is seldom seen in its acute form, although
the late, deforming, and chronic form still occurs sporadically
in the population, especially in thosewith origins in countries
with lower socioeconomic conditions.
The ratio of rheumatic (26%) versus nonrheumatic aortic
valves in our patient cohort was greater than previously
reported byDare et al. (9%) [2], lower than reported byWaller
et al. (43%) [19] and in the same range as reported by Passik
et al. (24%) [20]. Regional and population-based variability
in the incidence of rheumatic fever may account for some of
the differences, but probably also various definitions of the
rheumatic valve disease.
According to the literature, macroscopic features of RAS
are thickened and fused cusps dominated by fibrosis. Cal-
cification is very common according to Olsen [21] whereas
Schoen and Sutton [22] describes mineralization as only
a minor feature. The histological features are non-specific
consisting of thickening due to collagen tissue, destroyed
architecture, infiltration of inflammatory cells, and foci of
calcification and sometimes ossification. The Aschoff granu-
loma, which occasionally can be found in the form of Aschoff
and Anitschkow cells in valve tissue during the acute phase of
rheumatic fever, is not described in chronic disease.
However, studies are lacking that investigate chronic
rheumatic heart valve disease applying the inflammatory
criteria used for acquired NRAS. Chopra et al. [23–25]
described inflammatory changes in heart valve tissues from
patients with rheumatic heart disease, from India and New
Mexico, USA, but their studies mostly involved mitral valves
and only a few aortic valves.
One reason why studies dealing with histology of RAS
are sparse may be difficulties in how to define RAS contra
NRAS. Goffin et al. [4] chose 63 patients with carefully
verified history of rheumatic fever and used fibrotic scare
tissue and neovascularisation as histopathological markers
for diagnosis of rheumatic valve disease. One third of aortic
valves showed definite rheumatic heart valve disease fulfill-
ing both histopathological criteria, one third revealed only
functional changes, and the remaining third showed only
one of two criteria and was thus difficult to interpret. Even
in cases of concomitant rheumatic mitral valve disease, the
ratioswere similar andGoffin concluded that rheumatic heart
valve disease is principally a disease of the mitral valve.
In our study, 10 patients were considered to have aortic
valve disease of rheumatic origin, based on gross valvular
pathology of thickened and fused cusps. Three of them
revealed a history of rheumatic fever and, in addition, these
individuals had a rheumatic disease of the mitral valve. On
the other hand, the history of the remaining 7 subjects did
not include anything that threw suspicion on a previous,
serious streptococcal infection, neither did these subjects
reveal any mitral valve disease. The fact that 7/10 RAS valves
lacked a history of rheumatic fever and were devoid of
echocardiographic signs of mitral valve stenosis highlights
the question of a postinflammatory valvular disease of other
cause than rheumatic fever [3, 26, 27].
Our findings are also in line with a previous study by
Gallo et al. [3] who started out with 55 valves with postin-
flammatory scarring and divided them into three groups,
patients with both streptococcal infection and rheumatic
fever, patients with streptococcal infection without noncar-
diac major manifestations of rheumatic fever, and patients
without any of these features. The pathological examination
in that study was however unable to differentiate between
the three groups, since all valves showed the same general
pathological features. Gallo thus summarised that a postin-
flammatory valvular scarring of nonrheumatic aetiology
must exist.
Neovascularisation was seen in 12/29 (41%) NRAS and
3/10 (30%) RAS valves. Neovascularisation is considered
a non-specific postinflammatory sign and can be seen in





























Figure 3: (a) Degree of lymphocyte infiltration in RAS as compared to NRAS. Number of valves given as percent (%) of (𝑛). (b) Degree
of macrophage infiltration in RAS as compared to NRAS. Number of valves given as percent (%) of (𝑛). RAS = rheumatic aortic stenosis,
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Figure 4: Degree of apolipoprotein B and A-1 deposition in RAS as
compared toNRAS valves, data given as number of valves in percent
(%) of (𝑛). RAS = rheumatic aortic stenosis, NRAS = nonrheumatic
stenosis.
rheumatic heart valve disease, post endocarditis, atheroscle-
rosis, diabetes, cancer, and extracardiac inflammatory con-
ditions. Angiogenesis has also been demonstrated to be
distinctly associated with the inflammatory process in NRAS
[28]. Interestingly, as shown by Soini et al. [28], patients
receiving statin therapy had significantly lower presence of
neovessels.
Calcification constitutes a major feature of NRAS and is
also found, though to a lesser extent, in RAS [16]. In ourmate-
rial we found moderate to severe calcification in the majority
of RAS and NRAS valves. However, a distinct difference
was seen regarding the localisation of calcification. Whereas
NRAS-T mostly revealed calcification localised at the base
of the cusps, NRAS-B valves as well as RAS valves revealed
a significant higher proportion of diffuse calcification. The
difference in calcification between NRAS-B and NRAS-T is
previously described by Isner et al. [29]. They investigated
30 heavily calcified aortic valves and found nodular calcific
deposits in 11/16 NRAS-T and diffuse calcification in 14/14
NRAS-B. One possible explanation to the similar localisation
of calcification in RAS valves and NRAS-B valves could be
that the fusion between two cusps, independent of underlying
cause, give rise to similar mechanical and shear stress.
The thesis of cuspal inequality as an underlying cause
of valvular aortic stenosis has previously been presented
by Roberts [6] and was not contradicted by a study by
Vollebergh and Becker [30] showing that inequality in the
tricuspid aortic valve is a rule more than an exception. A
more or less pronounced inequality constituted by an unequal
tricuspid valve, a congenital bicuspid valve, or an acquired
fusion of cusps may thus lead to the development of chronic
inflammation and valve stenosis.
In general, the RAS valves revealed a somewhat lower
degree of T-lymphocyte infiltration when compared to
NRAS. Plasma cells were more commonly found in RAS
when compared to NRAS, with the lowest share in NRAS-T
valves. These figures suggest differences in the local inflam-
matory response although data are too limited to draw any
conclusions.
Macrophages were equally abundant in RAS and NRAS
valves, nor were there any significant differences regarding
deposition of apolipoproteins.
To summarize, most indices point towards a similar
and significant chronic inflammation in both types of aor-
tic stenotic valves, including neovascularisation, fibrosis,
destruction of valve architecture, infiltration ofmacrophages,
and deposition of apolipoproteins. The similarities regarding
the localisation of calcification in RAS and NRAS valves
also indicate that the valve anomaly/morphology, via its
mechanical and shear stress properties, can influence the
pathogenesis of aortic stenosis. Finally, our findings raise the
hypothesis that other inflammatory conditions rather than
rheumatic fever may give rise to the fusion of aortic cusps.
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The condition involving calcification, infiltration by
inflammatory cells, and deposition of lipoproteins resem-
bles the inflammatory process of atherosclerotic disease [7–
9, 11, 12, 31, 32]. In atherosclerosis, a cholesterol-lowering
and anti-inflammatory regimen is considered a cornerstone
of treatment. The similarities between calcific aortic valve
disease and atherosclerosis, both from a histopathological
and epidemiological point of view, raise the question whether
it is also possible to prevent or slow disease progression of
calcific aortic valve disease by cholesterol-lowering and anti-
inflammatory therapy. Further and ongoing studies on this
issue might give an answer to this question.
4.1. Study Limitations. Thepresent study is a small descriptive
and comparative study of RAS and NRAS. It focuses on
possible differences in histopathology, including inflamma-
tory features, but does not demonstrate any mechanistic
information regarding the pathogenesis of RAS and NRAS.
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